Annual CFF
$27.49 M
+$7.03 M+34.33%
31 December 2023
Summary:
Monte Rosa Therapeutics annual cash flow from financing activities is currently $27.49 million, with the most recent change of +$7.03 million (+34.33%) on 31 December 2023. During the last 3 years, it has fallen by -$32.57 million (-54.23%). GLUE annual CFF is now -92.72% below its all-time high of $377.56 million, reached on 31 December 2021.GLUE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$15.00 K
-$98.01 M-99.98%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly cash flow from financing activities is currently $15.00 thousand, with the most recent change of -$98.01 million (-99.98%) on 30 September 2024. Over the past year, it has dropped by -$1.09 million (-98.64%). GLUE quarterly CFF is now -99.99% below its all-time high of $205.47 million, reached on 30 June 2021.GLUE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$123.46 M
-$1.09 M-0.87%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM cash flow from financing activities is currently $123.46 million, with the most recent change of -$1.09 million (-0.87%) on 30 September 2024. Over the past year, it has increased by +$100.70 million (+442.60%). GLUE TTM CFF is now -68.82% below its all-time high of $395.98 million, reached on 30 June 2021.GLUE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.3% | -98.6% | +442.6% |
| 3 y3 years | -54.2% | -100.0% | -67.3% |
| 5 y5 years | - | - | - |
GLUE Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -92.7% | +34.3% | -100.0% | +106.9% | -67.3% | >+9999.0% |
| 5 y | 5 years | -92.7% | +83.3% | -100.0% | +106.9% | -68.8% | >+9999.0% |
| alltime | all time | -92.7% | +83.3% | -100.0% | +106.9% | -68.8% | >+9999.0% |
Monte Rosa Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $15.00 K(-100.0%) | $123.46 M(-0.9%) |
| June 2024 | - | $98.02 M(>+9900.0%) | $124.54 M(+349.3%) |
| Mar 2024 | - | $246.00 K(-99.0%) | $27.72 M(+0.8%) |
| Dec 2023 | $27.49 M(+34.3%) | $25.17 M(+2186.4%) | $27.49 M(+20.8%) |
| Sept 2023 | - | $1.10 M(-8.3%) | $22.75 M(+6.1%) |
| June 2023 | - | $1.20 M(+6566.7%) | $21.43 M(+5.4%) |
| Mar 2023 | - | $18.00 K(-99.9%) | $20.33 M(-0.7%) |
| Dec 2022 | $20.47 M | $20.43 M(-9516.6%) | $20.47 M(<-9900.0%) |
| Sept 2022 | - | -$217.00 K(-326.0%) | -$103.00 K(-100.3%) |
| June 2022 | - | $96.00 K(-37.3%) | $29.57 M(-87.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $153.00 K(-213.3%) | $234.95 M(-37.8%) |
| Dec 2021 | $377.56 M(+528.6%) | -$135.00 K(-100.5%) | $377.56 M(-0.0%) |
| Sept 2021 | - | $29.46 M(-85.7%) | $377.69 M(-4.6%) |
| June 2021 | - | $205.47 M(+43.9%) | $395.98 M(+95.2%) |
| Mar 2021 | - | $142.77 M(<-9900.0%) | $202.83 M(+237.7%) |
| Dec 2020 | $60.06 M(+300.4%) | -$10.00 K(-100.0%) | $60.06 M(-0.0%) |
| Sept 2020 | - | $47.75 M(+287.5%) | $60.07 M(+387.5%) |
| June 2020 | - | $12.32 M(>+9900.0%) | $12.32 M(>+9900.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
| Dec 2019 | $15.00 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual CFF year-on-year change?
- What is Monte Rosa Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly CFF year-on-year change?
- What is Monte Rosa Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM CFF year-on-year change?
What is Monte Rosa Therapeutics annual cash flow from financing activities?
The current annual CFF of GLUE is $27.49 M
What is the all time high annual CFF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual cash flow from financing activities is $377.56 M
What is Monte Rosa Therapeutics annual CFF year-on-year change?
Over the past year, GLUE annual cash flow from financing activities has changed by +$7.03 M (+34.33%)
What is Monte Rosa Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of GLUE is $15.00 K
What is the all time high quarterly CFF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly cash flow from financing activities is $205.47 M
What is Monte Rosa Therapeutics quarterly CFF year-on-year change?
Over the past year, GLUE quarterly cash flow from financing activities has changed by -$1.09 M (-98.64%)
What is Monte Rosa Therapeutics TTM cash flow from financing activities?
The current TTM CFF of GLUE is $123.46 M
What is the all time high TTM CFF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM cash flow from financing activities is $395.98 M
What is Monte Rosa Therapeutics TTM CFF year-on-year change?
Over the past year, GLUE TTM cash flow from financing activities has changed by +$100.70 M (+442.60%)